Analysis of a Protein-Binding Domain of p53

REFERENCES

• Aurora, R., and W. Herr. 1992. Segments of the POU domain influence one another’s DNA-binding specificity. Mol. Cell. Biol. 12:455–467.
   PubMedGoogle Scholar
• Baker, S. J., and B. Vogelstein. 1992. The p53 gene in human cancer, p. 105–116. In P. Sharp (ed.), Nuclear processes and oncogenes. Academic Press, San Diego, Calif.
   Google Scholar
• Bargonetti, J., P. N. Friedman, S. E. Kern, B. Vogelstein, and C. Prives. 1991. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65:1083–1091.
   PubMed Web of Science ®Google Scholar
• Bargonetti, J., I. Reynisdottir, P. Friedman, and C. Prives. 1992. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 6:1886–1898.
   PubMed Web of Science ®Google Scholar
• Blanar, M. A., and W. J. Rutter. 1992. Interaction cloning: identification of a helix-loop-helix protein that interacts with c-Fos. Science 256:1014–1018.
   PubMedGoogle Scholar
• Braithwaite, A. W., H.-W. Sturzbecher, C. Addison, C. Palmer, K. Rudge, and J. R. Jenkins. 1987. Mouse p53 inhibits SV40 origin-dependent DNA replication. Nature (London) 329:458–460.
   PubMed Web of Science ®Google Scholar
• Chen, P.-L., Y. Chen, R. Bookstein, and W.-H. Lee. 1990. Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576–1580.
   PubMed Web of Science ®Google Scholar
• Collins, K. L., and T. J. Kelly. 1991. Effects of T antigen and replication protein A on the initiation of DNA synthesis by DNA polymerase α-primase. Mol. Cell. Biol. 11:2108–2115.
   PubMed Web of Science ®Google Scholar
• Crawford, L., and E. Harlow. 1982. Uniform nomenclature for monoclonal antibodies directed against virus-coded proteins of simian virus 40 and polyomavirus. J. Virol. 41:709.
   PubMedGoogle Scholar
• Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (London) 356:215–221.
   PubMed Web of Science ®Google Scholar
• Dunn, S. D. 1986. Effects of the modification of transfer buffer composition and the renaturation of proteins in gels on the recognition of proteins on Western blots by monoclonal antibodies. Anal. Biochem. 157:144–153.
   PubMedGoogle Scholar
• Fanning, E., and R. Knippers. 1992. Structure and function of simian virus 40 large T antigen. Annu. Rev. Biochem. 61:55–85.
   PubMed Web of Science ®Google Scholar
• Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives. 1992. Wild-type p53 activates transcription in vitro. Nature (London) 358:83–86.
   PubMed Web of Science ®Google Scholar
• Frebourg, T., J. Kassel, K. T. Lam, M. A. Gryka, N. Barbier, T. I. Andersen, A.-L. Borresen, and S. H. Friend. 1992. Germline mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc. Natl. Acad. Sci. USA 89:6413–6417.
   PubMed Web of Science ®Google Scholar
• Friedman, P. N., S. E. Kern, B. Vogelstein, and C. Prives. 1990. Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen. Proc. Natl. Acad. Sci. USA 87:9275–9279.
   PubMedGoogle Scholar
• Gannon, J. V., R. Greaves, R. Iggo, and D. P. Lane. 1990. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1595–1602.
   PubMed Web of Science ®Google Scholar
• Gannon, J. V., and D. P. Lane. 1987. p53 and DNA polymerase a compete for binding to SV40 T antigen. Nature (London) 329:456–458.
   PubMed Web of Science ®Google Scholar
• Gannon, J. V., and D. P. Lane. 1990. Interactions between SV40 T antigen and DNA polymerase a. New Biol. 2:84–92.
   PubMedGoogle Scholar
• Gluzman, Y. 1981. SV40-transformed simian cells support the replication of early SV40 mutants. Cell 23:175–182.
   PubMed Web of Science ®Google Scholar
• Grueneberg, D. A., S. Natesan, C. Alexandre, and M. Z. Gilman. 1992. Human and Drosophila homeodomain proteins that enhance the DNA-binding activity of serum response factor. Science 257:1089–1095.
   PubMed Web of Science ®Google Scholar
• Helin, K., J. A. Lees, M. Vidal, N. Dyson, E. Harlow, and A. Fattaey. 1992. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 70:337–350.
   PubMed Web of Science ®Google Scholar
• Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49–53.
   PubMed Web of Science ®Google Scholar
• Huibregtse, J. M., M. Scheffner, and P. M. Howley. 1991. A cellular protein mediates association of p53 with the E6 onco-protein of human papillomavirus types 16 or 18. EMBO J. 10:4129–4135.
   PubMed Web of Science ®Google Scholar
• Jenkins, J. R., P. Chumakov, C. Addison, H.-W. Sturzbecher, and A. Wade-Evans. 1988. Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen. J. Virol. 62:3903–3906.
   PubMedGoogle Scholar
• Kaelin, W. G., W. Krek, W. R. Sellers, J. A. DeCaprio, F. Ajchenbaum, C. S. Fuchs, T. Chittenden, Y. Li, P. J. Farnham, M. A. Blanar, D. M. Livingston, and E. K. Flemington. 1992. Expression cloning of a cDNA encoding a retinoblastomabinding protein with E2F-like properties. Cell 70:351–364.
   PubMed Web of Science ®Google Scholar
• Kaelin, W. G., Jr., D. C. Pallas, J. A. DeCaprio, F. J. Kaye, and D. M. Livingston. 1991. Identification of cellular proteins that can interact specifically with the T/ElA-binding region of the retinoblastoma gene product. Cell 64:521–532.
   PubMed Web of Science ®Google Scholar
• Kao, C. C., P. R. Yew, and A. J. Berk. 1990. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 179:806–814.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587–597.
   PubMed Web of Science ®Google Scholar
• Kern, S. E., K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708–1711.
   PubMed Web of Science ®Google Scholar
• Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827–830.
   PubMed Web of Science ®Google Scholar
• Kornberg, A., and T. A. Baker. 1992. DNA replication. W. H. Freeman and Co., New York.
   Google Scholar
• Lai, J.-S., M. A. Cleary, and W. Herr. 1992. A single amino acid exchange transfers VP16-induced positive control from the Oct-1 to the Oct-2 homeo domain. Genes Dev. 6:2058–2065.
   PubMedGoogle Scholar
• Lai, J.-S., and W. Herr. 1992. Ethidium bromide provides a simple tool for identifying genuine DNA-independent protein associations. Proc. Natl. Acad. Sci. USA 89:6958–6962.
   PubMed Web of Science ®Google Scholar
• Lam, K. T., and S. K. Calderwood. 1992. HSP70 binds specifically to a peptide derived from the highly conserved domain (I) region of p53. Biochem. Biophys. Res. Commun. 184:167–174.
   PubMedGoogle Scholar
• Lane, D. P., and S. Benchimol. 1990. p 53: oncogene or antioncogene? Genes Dev. 4:1–8.
   PubMed Web of Science ®Google Scholar
• Lane, D. P., and J. Gannon. 1986. Monoclonal antibody analysis of the SV40 large T antigen-p53 complex. Cancer Cells 4:387–393.
   Google Scholar
• Lanford, R. E. 1988. Expression of simian virus 40 T antigen in insect cells using a baculovirus expression vector. Virology 167:72–81.
   PubMedGoogle Scholar
• Levine, A. J., J. Momand, and C. A. Finlay. 1991. The p53 tumour suppressor gene. Nature (London) 351:453–456.
   PubMed Web of Science ®Google Scholar
• Lin, J.-Y., and D. T. Simmons. 1991. The ability of large T antigen to complex with p53 is necessary for the increased life span and partial transformation of human cells by simian virus 40. J. Virol. 65:6447–6453.
   PubMedGoogle Scholar
• Ling, L. L., P. Keohavong, C. Dias, and W. G. Thilly. 1991. Optimization of the polymerase chain reaction with regard to fidelity: modified T7, Taq, and Vent DNA polymerases. PCR Methods Applic. 1:63–69.
   PubMedGoogle Scholar
• Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. D. Tlsty. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923–935.
   PubMed Web of Science ®Google Scholar
• Lu, X., S. H. Park, T. C. Thompson, and D. P. Lane. 1992. ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70:153–161.
   PubMedGoogle Scholar
• Melendy, T. E., and B. Stillman. 1993. An interaction between replication protein A and SV40 T antigen appears essential for primosome assembly during SV40 DNA replication. J. Biol. Chem. 268:3389–3395.
   PubMedGoogle Scholar
• Michalovitz, K. L., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671–680.
   PubMed Web of Science ®Google Scholar
• Milner, J., and E. A. Medcalf. 1991. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765–774.
   PubMed Web of Science ®Google Scholar
• Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245.
   PubMed Web of Science ®Google Scholar
• Montenarh, M. 1992. Biochemical properties of the growth suppressor/oncoprotein p53. Oncogene 7:1673–1680.
   PubMed Web of Science ®Google Scholar
• Pomerantz, J. L., T. M. Kristie, and P. A. Sharp. 1992. Recognition of the surface of a homeodomain protein. Genes Dev. 6:2047–2057.
   PubMedGoogle Scholar
• Prives, C. Personal communication.
   Google Scholar
• Qin, X.-Q., T. Chittenden, D. M. Livingston, and W. G. Kaelin, Jr. 1992. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 6:953–964.
   PubMed Web of Science ®Google Scholar
• Quartin, R. S., C. A. Finlay, and A. J. Levine. 1992. The p53 gene and gene product, p. 87–104. In P. Sharp (ed.), Nuclear processes and oncogenes. Academic Press, San Diego, Calif.
   Google Scholar
• Scheffner, M., T. Takahashi, J. M. Huibregtse, J. D. Minna, and P. M. Howley. 1992. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J. Virol. 66:5100–5105.
   PubMed Web of Science ®Google Scholar
• Shaulian, E., A. Zauberman, D. Ginsberg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12:5581–5592.
   PubMed Web of Science ®Google Scholar
• Simanis, V., and D. P. Lane. 1985. Immuno-affinity purification of SV40 large T antigen. Virology 144:88–100.
   PubMed Web of Science ®Google Scholar
• Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypeptides expressed in E. coli as fusions with glutathione-S- transferase. Gene 67:31–40.
   PubMed Web of Science ®Google Scholar
• Soussi, T., C. Caron de Fromentel, and P. May. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945–952.
   PubMed Web of Science ®Google Scholar
• Studier, F. W., A. H. Rosenberg, J. J. Dunn, and J. W. Dubendorff. 1990. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 185:60–89.
   PubMed Web of Science ®Google Scholar
• Sturzbecher, H.-W., R. Brain, C. Addison, K. Rudge, M. Remm, M. Grimaldi, E. Keenan, and J. R. Jenkins. 1992. A C-terminal α-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513–1523.
   PubMedGoogle Scholar
• Tan, T.-H., J. Wallis, and A. J. Levine. 1986. Identification of the p53 protein domain involved in formation of the simian virus 40 large T antigen-p53 protein complex. J. Virol. 59:574–583.
   PubMedGoogle Scholar
• Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523–526.
   PubMed Web of Science ®Google Scholar
• Wang, E. H., P. N. Friedman, and C. Prives. 1989. The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell 57:379–392.
   PubMed Web of Science ®Google Scholar
• Wilcock, D., and D. P. Lane. 1991. Localization of p53, retinoblastoma and host replication proteins at sites of viral replica-tion in herpes-infected cells. Nature (London) 349:429–431.
   PubMedGoogle Scholar
• Yin, Y., M. A. Tainsky, F. Z. Bischoff, L. C. Strong, and G. M. Wahl. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948.
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (London) 352:345–347.
   PubMed Web of Science ®Google Scholar
• Zakut-Houri, R., B. Bienz-Tadmor, D. Givol, and M. Oren. 1985. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J. 4:1251–1255.
   PubMed Web of Science ®Google Scholar
• Zhu, J., M. Abate, P. W. Rice, and C. N. Cole. 1991. The ability of simian virus 40 large T antigen to immortalize primary mouse embryo fibroblasts cosegregates with its ability to bind to p53. J. Virol. 65:6872–6880.
   PubMedGoogle Scholar